Skip to content

Camber launches generic Daliresp

PISCATAWAY, N.J. – Camber Pharmaceuticals announced the addition of roflumilast 250 mcg tablets to its current portfolio.

Table of Contents

PISCATAWAY, N.J. – Camber Pharmaceuticals announced the addition of roflumilast 250 mcg tablets to its current portfolio.

Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD, associated with chronic bronchitis and a history of exacerbations.

Roflumilast 250 mcg tablets are available in 20 and 28 unit-dose cartons.

Roflumilast tablets are also available in 500 mcg strength in 30 and 90 count bottles.

Comments

Latest